PulseAugur
EN
LIVE 01:10:15
中文(ZH) 阿斯利康据悉同百时美施贵宝洽谈合并

AstraZeneca, Bristol Myers Squibb reportedly explore merger talks

By PulseAugur Editorial · [2 sources] ·

AstraZeneca and Bristol Myers Squibb have reportedly engaged in early-stage merger discussions, though the talks are not guaranteed to result in a transaction. Such a combination would create a pharmaceutical giant with a significant presence in the US market. Bristol Myers Squibb is facing patent expirations for key drugs like Eliquis and Opdivo, but has seen growth from newer products. AI

RANK_REASON Merger talks between two major pharmaceutical companies. [lever_c_demoted from significant: ic=2 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 2 sources. How we write summaries →

AstraZeneca, Bristol Myers Squibb reportedly explore merger talks

COVERAGE [2]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    AstraZeneca reportedly in talks to merge with Bristol Myers Squibb

    据报道，阿斯利康已同百时美施贵宝洽谈合并事宜。知情人士称，这些商讨发生在近几个月内，且仍有可能告吹。报道并未详述任何潜在交易的具体架构。截至上周五，阿斯利康和百时美施贵宝的市值分别为1960亿英镑（约合2640亿美元）与1330亿美元。（界面）

  2. Fortune TIER_1 English(EN) · Dinesh Nair, Michelle F. Davis, Ashleigh Furlong, Kelly Gilblom, Bloomberg ·

    AstraZeneca said to have explored Bristol Myers merger

    Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.

RELATED ENTITIES

RELATED TOPICS